Product Details
| Product Name:
CWP232228 |
CAS No.:
1144044-02-9 |
| Purity:
98.87% |
Supply Ability:
10g |
| Release date:
2026/04/20 |
Product Introduction
Bioactivity
| Name | CWP232228 |
| Description | CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and liver cancer stem cells (CSC) without toxicity. |
| In vitro | CWP232228 (0.01-100 μM; 48 hours) inhibited cell proliferation, with IC50 values of 2 μM in mouse (4T1) and 0.8 μM in human (MDA-MB-435) breast cancer cell lines. In Hep3B, Huh7, and HepG2 cells, CWP232228 (0.01-10 μM; 48 hours) demonstrated IC50 values of 2.566, 2.630, and 2.596 μM, respectively. |
| In vivo | CWP232228 (100 mg/kg, administered i.p.; daily; mice with 4T1 cell tumors for 21 days; mice with MDA-MB-435 cell tumors for 60 days) significantly reduced tumor volume. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 60 mg/mL (83.61 mM), Sonication is recommended.
|
| Keywords | β-catenin | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | stem | signaling | liver | Inhibitor | inhibit | CWP-232228 | CWP232228 | CWP 232228 | cells | Cancer | Breast | beta-catenin | betacatenin | Beta catenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Urea | Wnt pathway activator 1 | Neohesperidin | XAV-939 | Ethyl linoleate | Monensin sodium salt | Nimbolide | Isoquercetin | (±)-Nornicotine | Methyl Vanillate | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Neuroprotective Compound Library | NO PAINS Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:1361200-34-1
$1330.00
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$140.00
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-20 |
United States